\-\ Texto\\:\\ \ \(0\)\
\-\ vs\\:\\ bp\\ 108\\-126\\/64\\-78\\ \\ rr\\ 20\\-24\\ hr\\ 114\\-170\\ t\\ 36\\.7\\-38\\.8\\ wt\\ 18\\.35kg\\ \ \(0\)\
\-\ gen\\:\\ thin\\ female\\.\\ yelling\\/crying\\ on\\ initial\\ exam\\ with\\ intermittent\\ calm\\ episodes\\.\\ distressed\\ in\\ appearance\\ and\\ not\\ smiling\\.\\ \ \(0\)\
\-\ heent\\:\\ nc\\/at\\.\\ eomi\\.\\ perrl\\.\\ glassy\\ sclera\\,\\ no\\ conjunctivitis\\.\\ no\\ eye\\ discharge\\.\\ tms\\ clear\\ bilaterally\\ and\\ well\\-visulaized\\.\\ no\\ tonsilar\\ exudate\\ with\\ some\\ erythema\\.\\ strawberry\\ tongue\\.\\ dry\\/cracked\\ lips\\.\\ no\\ rhinorrhea\\.\\ \ \(0\)\
\-\ neck\\:\\ supple\\,\\ no\\ lymphadenopathy\\.\\ no\\ rigidity\\.\\ \ \(0\)\
\-\ pulm\\:\\ ctab\\.\\ good\\ air\\ entry\\.\\ no\\ wheeze\\/rhonchi\\/rales\\.\\ \ \(0\)\
\-\ cv\\:\\ rrr\\,\\ nomral\\ s1\\/s2\\.\\ no\\ murmur\\.\\ 2\\+\\ pulses\\.\\ cr\\ \\<\\ 2sec\\.\\ \ \(0\)\
\-\ abd\\:\\ soft\\,\\ nd\\.\\ \\+bs\\,\\ no\\ masses\\ or\\ hsm\\.\\ no\\ palpable\\ bladder\\ edge\\.\\ \\ crying\\ throughout\\ exam\\ and\\ unable\\ to\\ localize\\ pain\\.\\ \ \(0\)\
\-\ gu\\:\\ \\ tanner\\ 1\\ female\\.\\ minimal\\ erythema\\ at\\ opening\\ of\\ vagina\\ with\\ normal\\ labia\\.\\ no\\ lesions\\.\\ \ \(0\)\
\-\ ext\\/msk\\:\\ from\\ all\\ extremities\\.\\ no\\ edmea\\.\\ crying\\ with\\ palpation\\ of\\ all\\ extremities\\,\\ pale\\ but\\ not\\ cool\\.\\ \ \(0\)\
\-\ neuro\\:\\ unable\\ to\\ complete\\ exam\\ with\\ poor\\ cooperation\\.\\ extremely\\ hypersensative\\ to\\ touch\\.\\ responds\\ normally\\ to\\ parents\\.\\ tone\\ and\\ strength\\ seem\\ appropriate\\.\\ not\\ able\\ to\\ check\\ stance\\/gait\\.\\ \ \(0\)\
\-\ derm\\:\\ fine\\,\\ pink\\,\\ sandpaper\\ type\\ rash\\ on\\ back\\ and\\ upper\\ extremities\\.\\ \ \(0\)\
\-\ admit\\ labs\\:\\ \ \(0\)\
\-\ wbc\\:\\ 32\\.4\\ h\\/h\\ 11\\.2\\/34\\ platelet\\ 654\\ \\ diff\\.\\ 1\\ band\\ 92\\ segs\\ 5\\ lymph\\ 2\\ mono\\ anc\\ 30\\.13\\ \ \(0\)\
\-\ ua\\ cath\\ specimen\\:\\ ph\\ 7\\.5\\,\\ specific\\ gravity\\ 1\\.016\\,\\ otherwise\\ negative\\ \ \(0\)\
\-\ na\\ 135\\ k\\ 3\\.9\\ cl\\ 99\\ co2\\ 23\\.6\\ glucose\\ 99\\ bun\\ 6\\ cr\\ 0\\.4\\ \ \(0\)\
\-\ urin\\ culture\\:\\ \\>\\ 100\\,000\\ col\\/ml\\ enterococcus\\ \\(group\\ d\\ strep\\)\\ \ \(0\)\
\-\ crp\\ 3\\.35\\ \ \(0\)\
\-\ esr\\ 66\\ \ \(0\)\
\-\ ldh\\ 153\\ \ \(0\)\
\-\ hepatic\\ function\\:\\ albumin\\ 3\\.4\\,\\ alk\\ phos\\ 199\\,\\ tbili\\ 0\\.2\\,\\ dbili\\ 0\\.0\\,\\ ibili\\ 0\\.2\\,\\ ast\\ 14\\,\\ alt\\ 20\\,\\ tprotein\\ 7\\.5\\,\\ amylase\\ 34\\,\\ lipase\\ 305\\ \ \(0\)\
\-\ csf\\:\\ glucose\\ 48\\,\\ protein\\ 57\\.6\\,\\ neutrophil\\ 43\\,\\ lymphocyte\\ 23\\,\\ monocyte\\/macrophage\\ 34\\,\\ wbc\\ 245\\,\\ rbc\\ 8\\ \ \(0\)\
\-\ ferretin\\ 155\\ \ \(0\)\
\-\ normal\\ studies\\:\\ blood\\ culture\\,\\ rapid\\ strep\\ and\\ throat\\ culture\\,\\ csf\\ culture\\,\\ spinal\\ fluid\\ analysis\\,\\ ana\\,\\ rf\\,\\ cmv\\ titers\\,\\ ebv\\ titers\\,\\ hiv\\,\\ rpr\\,\\ borrelia\\ burgdorferi\\ abs\\,\\ mycoplasma\\ p\\.\\ igg\\ \\&\\ igm\\,\\ acute\\ leukemia\\ profile\\,\\ aso\\ titer\\,\\ anti\\-dnase\\ b\\,\\ multiple\\ sclerosis\\ panel\\ 2\\,\\ triglyceride\\,\\ fibrinogen\\,\\ total\\ ck\\,\\ uric\\ acid\\.\ \(0\)\
\-\ multiple\\ sclerosis\\ panel2\\:\\ oligoclonal\\ banding\\ csf\\ pending\\.\\ \\ myelin\\ basic\\ protein\\ 5\\.1\\ \\(reference\\ range\\ 4\\.1\\-6\\.0\\ weakly\\ positive\\)\\.\\ \\ albumin\\ 4\\.8\\.\\ albumin\\ csf\\ 30\\.8\\.\\ igg\\ csf\\ 2\\.5\\.\\ immunoglobulin\\ g\\ 699\\.\\ igg\\ synthesis\\ rate\\ 0\\.2\\ \\(neg\\)\\.\\ igg\\ index\\ 0\\.55\ \(0\)\
\-\ consult\\ services\\:\\ id\\,\\ neurology\\,\\ rheumatology\\,\\ heme\\/onc\\,\\ opthamology\\,\\ urology\\.\\ \ \(0\)\
\-\ patient\\ was\\ admitted\\ to\\ the\\ general\\ medical\\ floor\\ for\\ evaluation\\ and\\ management\\.\\ there\\ was\\ initial\\ concern\\ for\\ an\\ infectious\\ etiology\\ with\\ the\\ patient\\‚\\Ä\\ôs\\ history\\ of\\ fevers\\ and\\ confusion\\.\\ \\ serial\\ blood\\ cultures\\ were\\ all\\ no\\ growth\\.\\ \\ the\\ patient\\ was\\ empirically\\ started\\ on\\ vancomycin\\,\\ rocephin\\ and\\ acyclovir\\.\\ initial\\ positive\\ urin\\ culture\\ was\\ thought\\ to\\ have\\ been\\ secondary\\ to\\ repeated\\ catherizations\\.\\ \\ acyclrovir\\ was\\ stopped\\ once\\ hsv\\ pcr\\ was\\ negative\\,\\ and\\ the\\ rest\\ of\\ antibiotic\\ regimen\\ was\\ completed\\ for\\ a\\ ten\\ day\\ course\\.\\ this\\ was\\ not\\ thought\\ to\\ be\\ an\\ infectious\\ process\\ after\\ review\\ of\\ the\\ laboratory\\ study\\ results\\.\\ \\ no\\ noted\\ masses\\ on\\ imaging\\,\\ a\\ normal\\ bone\\ scan\\,\\ and\\ a\\ normal\\ bone\\ marrow\\ aspirate\\ analysis\\ made\\ the\\ concern\\ for\\ malignancy\\ less\\ likely\\.\\ \\ presenting\\ complaint\\ of\\ diffuse\\ pain\\ and\\ fever\\ with\\ strong\\ family\\ history\\ of\\ autoimmune\\ disease\\ raised\\ concern\\ for\\ a\\ possible\\ rheumatologic\\ disorder\\ such\\ as\\ jia\\ or\\ sle\\.\\ with\\ laboratory\\ evaluation\\,\\ the\\ consulting\\ rheumatologist\\ thought\\ that\\ the\\ patient\\‚\\Ä\\ôs\\ presentation\\ was\\ more\\ consistent\\ with\\ a\\ possible\\ vasculitis\\.\\ \ \(0\)\
\-\ on\\ further\\ neurological\\ examination\\,\\ the\\ patient\\ was\\ noted\\ to\\ have\\ bilateral\\ clonus\\ and\\ weakness\\ of\\ the\\ lower\\ extremities\\.\\ she\\ received\\ three\\ days\\ of\\ high\\ dose\\ steroid\\ therapy\\ after\\ which\\ she\\ had\\ remarkable\\ improvement\\ in\\ her\\ symptoms\\.\\ \\ she\\ was\\ ddischarged\\ home\\ after\\ a\\ ten\\ day\\ hospitalization\\ with\\ out\\-patient\\ follow\\-up\\ with\\ neurology\\ and\\ rheumatology\\ with\\ the\\ diagnosis\\ of\\ transverse\\ mellitus\\.\ \(0\)\
\-\ however\\,\\ she\\ returned\\ to\\ the\\ ed\\ just\\ five\\ days\\ after\\ her\\ discharge\\ home\\ and\\ was\\ readmitted\\ to\\ the\\ hospital\\ for\\ recurrence\\ of\\ symptoms\\ that\\ included\\:\\ head\\ ache\\,\\ urinary\\ retention\\,\\ change\\ in\\ mental\\ status\\/confusion\\,\\ and\\ difficulty\\ with\\ ambulation\\,\\ fever\\ and\\ left\\ eye\\ drifting\\.\\ further\\ laboratory\\ and\\ imaging\\ studies\\ were\\ obtained\\ and\\ no\\ infectious\\ cause\\ identified\\.\\ \\ preliminary\\ diagnoses\\ of\\ transverse\\ meylitis\\ from\\ the\\ first\\ hospital\\ admit\\ was\\ reconsidered\\.\\ during\\ her\\ second\\ admission\\,\\ she\\ received\\ five\\ days\\ of\\ iv\\ steroid\\ therapy\\.\\ \\ she\\ had\\ resolution\\ of\\ her\\ symptoms\\ and\\ was\\ discharged\\ home\\ on\\ continued\\ oral\\ steroid\\ therapy\\.\\ \\ final\\ diagnosis\\ upon\\ discharge\\ home\\ with\\ consideration\\ of\\ laboratory\\ and\\ imaging\\ evaluation\\ and\\ consulting\\ expertise\\ was\\ adem\\.\ \(0\)\
\-\ 4\\/20\\ mri\\ c\\/t\\/l\\ w\\/o\\ \\&\\ w\\ cntr\\:\\ \\ impression\\:\\ suggestion\\ of\\ very\\ subtle\\/mild\\ t2\\ prolongation\\ in\\ the\\ central\\ white\\ matter\\ of\\ the\\ cord\\ from\\ about\\ c4\\-t2\\.\\ this\\ could\\ potentially\\ represent\\ early\\/mild\\ transverse\\ myelitis\\.\\ \ \(0\)\
\-\ 4\\/20\\ mri\\ brain\\ w\\/o\\ \\&\\ w\\,\\ cow\\ mra\\:\\ impression\\:\\ 1\\.\\ the\\ mild\\ t2\\ prolongation\\ in\\ the\\ cerebral\\ sulci\\ described\\ on\\ yesterday\\'s\\ exam\\ is\\ again\\ seen\\ on\\ the\\ axial\\ flair\\ images\\,\\ however\\ this\\ finding\\ is\\ seen\\ fairly\\ frequently\\ in\\ patient\\'s\\ receiving\\ supplemental\\ oxygen\\ during\\ brain\\ mri\\ and\\ is\\ likely\\ not\\ clinically\\ significant\\.\\ 2\\.\\ pineal\\ cyst\\.\\ 3\\.\\ otherwise\\ normal\\ study\\.\\ \\ \\ \ \(0\)\
\-\ nuc\\ bone\\ scan\\ whole\\ body\\ ecg\\ and\\ echo\\:\\ \\ normal\\ study\\ \ \(0\)\
\-\ 4\\/28\\ mri\\ brain\\ w\\/\\ \\&\\ w\\/o\\ contrast\\:\\ \\ impression\\:\\ questionable\\ area\\ of\\ increased\\ signal\\ at\\ the\\ body\\ of\\ the\\ corpus\\ callosum\\ is\\ felt\\ to\\ represent\\ volume\\ averaging\\ of\\ adjacent\\ cortical\\ gray\\ matter\\.\\ the\\ brain\\ has\\ a\\ normal\\ appearance\\ without\\ evidence\\ of\\ breakdown\\ of\\ the\\ blood\\-brain\\ barrier\\.\\ \ \(0\)\
\-\ 5\\/4\\ mri\\ brain\\ w\\/\\ and\\ w\\/o\\ contrast\\:\\ impression\\:\\ small\\ patchy\\ areas\\ of\\ t2\\ prolongation\\ are\\ now\\ demonstrated\\ in\\ the\\ white\\ matter\\ of\\ the\\ cerebral\\ hemispheres\\,\\ right\\ corpus\\ callosum\\,\\ right\\ cerebral\\ peduncle\\,\\ and\\ middle\\ cerebellar\\ peduncles\\ bilaterally\\.\\ given\\ the\\ patient\\'s\\ clinical\\ history\\,\\ this\\ may\\ represent\\ acute\\ disseminated\\ encephalomyelitis\\ \\(adem\\)\\.\\ although\\ less\\ likely\\,\\ the\\ differential\\ diagnosis\\ would\\ also\\ include\\ childhood\\ onset\\ of\\ multiple\\ sclerosis\\.\\ \ \(0\)\
\-\ 5\\/5\\ ir\\ angio\\ carotid\\ cerebral\\ bilat\\ sel\\:\\ normal\\ cerebral\\ angiogram\\.\ \(0\)\
\-\ acute\\ disseminated\\ encephalomyelitis\ \(7\)\
\-\ \\‚\\Ä\\¢\\ multiple\\ sclerosis\\ \\(ms\\)\ \(0\)\
\-\ \\‚\\Ä\\¢\\ acute\\ disseminated\\ encephalomyelitis\\ \\(adem\\)\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\ acute\\ hemorrhagic\\ encephalomyelitis\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\ progressive\\ multifocal\\ leukoencephalitis\\ \\(pml\\)\ \(0\)\
\-\ \\‚\\Ä\\¢\\ subacute\\ sclerosing\\ panencephalitis\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\ collagen\\ vascular\\ disease\\ \ \(1\)\
\-\ \\‚\\Ä\\¢\\ optic\\ neuritis\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\ transverse\\ myelitis\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\ neuromyelitis\\ optica\\ \\(devic\\‚\\Ä\\ôs\\ disease\\)\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\ acute\\ inflammatory\\ demyelinating\\ polyneuropathy\\ \\(aidp\\,\\ guillain\\-barre\\ syndrome\\)\ \(0\)\
\-\ 4\\ y\\/o\\ previously\\ healthy\\ girl\\ presentsto\\ the\\ ed\\ with\\ a\\ two\\ week\\ history\\ of\\ fever\\,\\ pna\\ for\\ which\\ she\\ was\\ treated\\ with\\ two\\ courses\\ of\\ antibiotics\\,\\ worsening\\ abdominal\\ pain\\,\\ urinary\\ retention\\ and\\ increased\\ difficulty\\ with\\ ambulation\\.\\ \\ during\\ this\\ two\\ week\\ time\\ frame\\,\\ she\\ had\\ a\\ bowel\\ clean\\ out\\ and\\ required\\ three\\ straight\\ catheterizations\\ for\\ urinary\\ retention\\.\\ \\ she\\ had\\ been\\ seen\\ by\\ her\\ primary\\ care\\ provider\\ and\\ in\\ the\\ ed\\ with\\ treatment\\ for\\ presumed\\ pna\\,\\ constipation\\,\\ and\\ urinary\\ retention\\ on\\ several\\ occurrences\\ over\\ these\\ past\\ two\\ weeks\\.\\ \\ parents\\ expressed\\ concern\\ for\\ weight\\ loss\\ of\\ approximately\\ three\\ pounds\\ during\\ this\\ time\\ frame\\.\\ \\ the\\ mother\\ also\\ reported\\ that\\ the\\ patient\\ seemed\\ very\\ sensitive\\ to\\ touch\\ and\\ movement\\ as\\ if\\ \\‚\\Ä\\úeverything\\ hurt\\ her\\‚\\Ä\\ù\\ over\\ the\\ preceding\\ days\\ to\\ her\\ admission\\.\ \(0\)\
\-\ this\\ patient\\‚\\Ä\\ôs\\ initial\\ presentation\\ was\\ concerning\\ for\\ autoimmune\\ and\\/or\\ infectious\\ etiology\\ affecting\\ her\\ central\\ nervous\\ system\\.\\ \\ preliminary\\ diagnosis\\ of\\ acute\\ transverse\\ myelitis\\,\\ sometimes\\ refered\\ to\\ as\\ acute\\ transverse\\ myelopathy\\,\\ \\ is\\ characterized\\ by\\ an\\ acutely\\ developing\\,\\ rapidly\\ progressing\\ lesion\\ affecting\\ the\\ spinal\\ cord\\.\\ \\ onset\\ of\\ disease\\ may\\ occur\\ during\\ active\\ infection\\ or\\ as\\ a\\ post\\-infectious\\ demyelinating\\ disorder\\.\\ \\ cases\\ have\\ also\\ been\\ reported\\ post\\-vaccination\\,\\ autoimmune\\ or\\ as\\ systemic\\ malignancy\\.\\ \\ any\\ segment\\ of\\ the\\ spinal\\ column\\ may\\ be\\ affected\\,\\ although\\ there\\ is\\ increased\\ predominance\\ for\\ the\\ thoracic\\ cord\\ with\\ multilevel\\ involvement\\ common\\.\\ \\ neuroimaging\\ is\\ recommended\\ for\\ evaluation\\ of\\ conditions\\ that\\ can\\ mimic\\ acute\\ transverse\\ myelitis\\:\\ acute\\ disk\\ herniation\\,\\ hematoma\\,\\ epidural\\ abscess\\,\\ or\\ compression\\ myelopathies\\.\\ \\ during\\ the\\ acute\\ phase\\,\\ mr\\ scans\\ can\\ be\\ normal\\ and\\ nonspecific\\.\\ \\ t1\\ may\\ show\\ focal\\ cord\\ enlargement\\ and\\ t2\\ with\\ poorly\\ delineated\\ hyperintensities\\ as\\ the\\ most\\ commonly\\ identified\\ abnormalities\\.\\ \ \(0\)\
\-\ with\\ the\\ presumptive\\ diagnosis\\ of\\ transverse\\ myelitis\\,\\ multiple\\ sclerosis\\ \\(ms\\)\\ was\\ also\\ considered\\.\\ \\ although\\ ms\\ is\\ considered\\ an\\ adult\\ disease\\,\\ symptoms\\ can\\ begin\\ during\\ childhood\\ \\(before\\ the\\ age\\ of\\ 5\\)\\.\\ \\ presenting\\ symptoms\\ can\\ be\\ as\\ subtle\\ as\\ school\\ problems\\ to\\ more\\ pronounced\\ with\\ paresthesias\\,\\ cerebral\\ edema\\,\\ meningismus\\ and\\ impaired\\ consciousness\\.\\ \\ mr\\ imaging\\ is\\ the\\ study\\ of\\ choice\\ in\\ diagnosis\\ of\\ ms\\ and\\ in\\ the\\ evaluation\\ of\\ disseminated\\ lesions\\.\\ \\ lesions\\ typically\\ are\\ sharply\\ marginated\\ with\\ prolongation\\ of\\ t1\\ and\\ t2\\ relaxation\\ times\\.\\ \\ t2\\-weighted\\ images\\ might\\ show\\ a\\ central\\ area\\ of\\ very\\ high\\ signal\\ intensity\\ surrounded\\ by\\ peripheral\\ area\\ of\\ moderately\\ high\\ intensity\\.\\ \\ new\\ lesions\\ generally\\ enhance\\ on\\ average\\ for\\ three\\ weeks\\.\\ \\ tumefactive\\ plaques\\ in\\ the\\ brainstem\\ and\\ spinal\\ cord\\ might\\ be\\ present\\ with\\ extensive\\ swelling\\ with\\ mr\\ signal\\ changes\\ suggestive\\ of\\ neoplasm\\.\\ \\ tumefactive\\ plaques\\ may\\ be\\ differentiated\\ from\\ tumors\\ by\\ presence\\ of\\ other\\ typical\\ plaques\\ and\\ lack\\ of\\ mass\\ effect\\.\\ \\ plaques\\ will\\ be\\ adjacent\\ to\\ ventricular\\ surface\\ and\\ enhancement\\ will\\ be\\ limited\\ to\\ one\\ side\\ of\\ the\\ lesion\\.\\ \\ \\ some\\ ms\\ lesions\\ will\\ have\\ higher\\ intensity\\ on\\ precontrast\\ t1\\-weighted\\ images\\ necessitating\\ precontrast\\ and\\ postcontrast\\ evaluation\\ if\\ magnetization\\ transfer\\ is\\ used\\.\\ \\ magnetization\\ transfer\\,\\ diffusion\\ tensor\\ imaging\\ that\\ shows\\ reduced\\ anisotropy\\ in\\ affected\\ white\\ matter\\,\\ and\\ flair\\ sequences\\ will\\ show\\ abnormalities\\ in\\ ms\\ patients\\ in\\ cases\\ where\\ mr\\ may\\ appear\\ normal\\.\\ \\ magnetization\\ transfer\\ techniques\\ are\\ also\\ helpful\\ in\\ distinguishing\\ inflammation\\ that\\ occurs\\ in\\ ms\\ from\\ demylination\\,\\ which\\ demonstrates\\ more\\ reduction\\ of\\ magnetization\\ transfer\\.\\ \\ \\ \ \(0\)\
\-\ another\\ difficult\\ distinction\\ to\\ make\\ is\\ that\\ between\\ ms\\ and\\ acute\\ disseminated\\ encephalomyelitis\\ \\(adem\\)\\.\\ \\ adem\\ has\\ also\\ been\\ referred\\ to\\ as\\ paainfectious\\ encephalomyelitis\\.\\ \\ it\\ is\\ an\\ immune\\-mediated\\ response\\ to\\ a\\ preceding\\ viral\\ infection\\,\\ vaccination\\ and\\ less\\ commonly\\ a\\ bacterial\\ infection\\ or\\ drug\\ ingestion\\.\\ \\ acute\\ demyelination\\ is\\ thought\\ to\\ be\\ caused\\ by\\ antibody\\-antigen\\ complexes\\.\\ \\ perivascular\\,\\ mostly\\ perivenular\\,\\ inflammatory\\ \\(mostly\\ mononuclear\\)\\ infiltrates\\ are\\ seen\\.\\ with\\ disease\\ resolution\\,\\ there\\ is\\ increased\\ perivascular\\ astrocytosis\\.\\ incidence\\ in\\ unknown\\ with\\ occurrence\\ seen\\ in\\ all\\ ages\\,\\ although\\,\\ most\\ cases\\ are\\ seen\\ in\\ children\\ and\\ young\\ adults\\.\\ \\ there\\ is\\ typically\\ abrupt\\ onset\\ with\\ neurologic\\ symptoms\\ evident\\ in\\ one\\ to\\ three\\ weeks\\ after\\ insult\\.\\ there\\ is\\ a\\ rapid\\ clinical\\ course\\ with\\ multifocal\\ symptoms\\ consisting\\ of\\ but\\ not\\ limited\\ to\\:\\ headache\\,\\ fever\\,\\ vomiting\\,\\ nuchal\\ rigidity\\,\\ seizures\\,\\ focal\\ neurologic\\ deficits\\,\\ coma\\ and\\ death\\.\\ some\\ patients\\ will\\ have\\ full\\ recovery\\ while\\ others\\ may\\ have\\ permanent\\ neurologic\\ impairment\\ \\(10\\-30\\%\\)\\.\\ \\ neurologic\\ findings\\ typically\\ evolve\\ and\\ resolve\\ over\\ several\\ weeks\\.\\ \\ mr\\ is\\ preferred\\ to\\ ct\\ in\\ evaluating\\ for\\ adem\\.\\ \\ multifocal\\ subcortical\\ hyperintense\\ foci\\ are\\ present\\ on\\ t2\\-weighted\\ images\\.\\ \\ the\\ disease\\ process\\ can\\ involve\\ the\\ deep\\ white\\ matter\\,\\ brainstem\\,\\ and\\ cerebellum\\.\\ \\ cortical\\ and\\ deep\\ gray\\ matter\\ may\\ be\\ involved\\,\\ although\\ to\\ a\\ lesser\\ extent\\ than\\ white\\ matter\\.\\ \\ moderate\\ to\\ large\\ areas\\ of\\ demylination\\ \\(prolonged\\ t1\\ and\\ t2\\ on\\ mr\\)\\ can\\ be\\ found\\ on\\ subcortical\\ white\\ matter\\.\\ \\ lesions\\ are\\ usually\\ bilateral\\ but\\ asymmetric\\.\\ \\ adem\\ is\\ usually\\ nonhemorrhagic\\ on\\ mr\\.\\ some\\ lesions\\ may\\ also\\ enhance\\ with\\ contrast\\ administration\\.\\ periventricular\\ white\\ matter\\ is\\ involved\\ in\\ half\\ of\\ patients\\ with\\ adem\\,\\ whereas\\,\\ 90\\%\\ involvement\\ may\\ be\\ seen\\ in\\ ms\\.\\ \\ the\\ corpus\\ callosum\\ is\\ more\\ commonly\\ involved\\ in\\ ms\\ than\\ adem\\.\\ \\ mr\\ may\\ demonstrate\\ abnormalities\\ of\\ the\\ deep\\ cerebral\\ nuclei\\ in\\ as\\ many\\ as\\ 50\\%\\ of\\ pediatric\\ patients\\.\\ \\ \ \(0\)\
\-\ in\\ differentiation\\ adem\\ from\\ vasculitis\\,\\ diffusion\\ images\\ show\\ increased\\ water\\ motion\\ in\\ the\\ foci\\ of\\ demyelination\\ in\\ the\\ acute\\ and\\ subacute\\ phase\\ of\\ adem\\.\\ \\ lesions\\ from\\ vasculitis\\ show\\ reduced\\ diffusion\\ in\\ the\\ acute\\ phase\\.\\ \\ in\\ adem\\,\\ t2\\ changes\\ in\\ the\\ brain\\ evolve\\ with\\ time\\ and\\ typically\\ correlate\\ to\\ the\\ clinical\\ symptoms\\.\\ \\ follow\\-up\\ mr\\ studies\\ may\\ show\\ worsening\\ as\\ clinical\\ symptoms\\ begin\\ to\\ improve\\.\\ \\ with\\ concern\\ for\\ vasculitis\\,\\ vascular\\ imaging\\ may\\ illustrate\\ vasculitis\\ or\\ venous\\ occlusion\\ and\\ focal\\ infarcts\\.\\ \ \(0\)\
\-\ there\\ are\\ a\\ number\\ of\\ disorders\\ that\\ may\\ present\\ with\\ acute\\ neurologic\\ findings\\ similar\\ to\\ our\\ patient\\ and\\ should\\ be\\ considered\\ in\\ the\\ differential\\ during\\ the\\ evaluation\\ and\\ management\\.\\ \\ etiology\\ may\\ be\\ infectious\\,\\ autoimmune\\/immunologic\\,\\ traumatic\\,\\ or\\ oncologic\\.\\ \\ thorough\\ and\\ appropriate\\ laboratory\\ and\\ imaging\\ evaluation\\ will\\ guide\\ medical\\ diagnosis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ adem\\:\\ 0\\.02820414294436233\ \(0\)\
\-\ ms\\:\\ 0\\.020834959771519793\ \(0\)\
\-\ \\:\\:\\ 0\\.017015998598399612\ \(0\)\
\-\ magnetization\\:\\ 0\\.016086712452493608\ \(0\)\
\-\ encephalomyelitis\\:\\ 0\\.015669186050934807\ \(0\)\
\-\ acute\\:\\ 0\\.015400579044572957\ \(0\)\
\-\ \\,\\:\\ 0\\.014078899392778631\ \(0\)\
\-\ matter\\:\\ 0\\.013814014477010575\ \(0\)\
\-\ myelitis\\:\\ 0\\.013645768886656664\ \(0\)\
\-\ may\\:\\ 0\\.012826152159430592\ \(0\)\
\-\ transverse\\:\\ 0\\.012505279905656924\ \(0\)\
\-\ disseminated\\:\\ 0\\.011871807735680367\ \(0\)\
\-\ mr\\:\\ 0\\.011148173014378607\ \(0\)\
\-\ transfer\\:\\ 0\\.011145015005226803\ \(0\)\
\-\ prolongation\\:\\ 0\\.011027243981253132\ \(0\)\
\-\ igg\\:\\ 0\\.010713648621897916\ \(0\)\
\-\ retention\\:\\ 0\\.010446124033956537\ \(0\)\
\-\ culture\\:\\ 0\\.010385124422730799\ \(0\)\
\-\ vasculitis\\:\\ 0\\.009974605765228515\ \(0\)\
\-\ she\\:\\ 0\\.009849030690277167\ \(0\)\
\-\ concern\\:\\ 0\\.009697012391648408\ \(0\)\
\-\ during\\:\\ 0\\.00954382937928397\ \(0\)\
\-\ cerebral\\:\\ 0\\.009453980616947306\ \(0\)\
\-\ her\\:\\ 0\\.009377414811988815\ \(0\)\
\-\ evaluation\\:\\ 0\\.009059265678200028\ \(0\)\
\-\ white\\:\\ 0\\.009050515277821225\ \(0\)\
\-\ w\\/o\\:\\ 0\\.008807544484310627\ \(0\)\
\-\ symptoms\\:\\ 0\\.008744031611351849\ \(0\)\
\-\ plaques\\:\\ 0\\.008708881671773628\ \(0\)\
\-\ be\\:\\ 0\\.008416329437415606\ \(0\)\
\-\ infectious\\:\\ 0\\.008380143402061674\ \(0\)\
\-\ lesions\\:\\ 0\\.008348760972058203\ \(0\)\
\-\ impression\\:\\ 0\\.008333983908607918\ \(0\)\
\-\ csf\\:\\ 0\\.008139813758681596\ \(0\)\
\-\ neurologic\\:\\ 0\\.008139813758681596\ \(0\)\
\-\ was\\:\\ 0\\.008115417609418961\ \(0\)\
\-\ urin\\:\\ 0\\.008043356226246804\ \(0\)\
\-\ 4\\/20\\:\\ 0\\.008043356226246804\ \(0\)\
\-\ 0\\.2\\:\\ 0\\.007834593025467403\ \(0\)\
\-\ t2\\:\\ 0\\.007723595520644372\ \(0\)\
\-\ albumin\\:\\ 0\\.00755430870159056\ \(0\)\
\-\ autoimmune\\:\\ 0\\.007456509024607697\ \(0\)\
\-\ home\\:\\ 0\\.007412277797190025\ \(0\)\
\-\ demylination\\:\\ 0\\.007410922667341745\ \(0\)\
\-\ cord\\:\\ 0\\.007406874817986773\ \(0\)\
\-\ will\\:\\ 0\\.007317922495563345\ \(0\)\
\-\ urinary\\:\\ 0\\.007218441641614646\ \(0\)\
\-\ laboratory\\:\\ 0\\.007183147207696318\ \(0\)\
\-\ show\\:\\ 0\\.0071801713535354725\ \(0\)\
\-\ thought\\:\\ 0\\.00717648996602213\ \(0\)\
\-\ \\‚\\Ä\\¢\\:\\ 0\\.007148788100346203\ \(0\)\
\-\ as\\:\\ 0\\.0070761542293474155\ \(0\)\
\-\ brain\\:\\ 0\\.007038370957945517\ \(0\)\
\-\ sclerosis\\:\\ 0\\.007001175258727976\ \(0\)\
\-\ pna\\:\\ 0\\.006778489108436685\ \(0\)\
\-\ although\\:\\ 0\\.006582867884526924\ \(0\)\
\-\ three\\:\\ 0\\.006570766944221967\ \(0\)\
\-\ consulting\\:\\ 0\\.006408539192279601\ \(0\)\
\-\ precontrast\\:\\ 0\\.006408539192279601\ \(0\)\
\-\ imaging\\:\\ 0\\.006393483928462235\ \(0\)\
\-\ multifocal\\:\\ 0\\.00629016065527882\ \(0\)\
\-\ admit\\:\\ 0\\.006267890761780278\ \(0\)\
\-\ diagnosis\\:\\ 0\\.006266211366543312\ \(0\)\
\-\ steroid\\:\\ 0\\.006174434303050632\ \(0\)\
\-\ in\\:\\ 0\\.006151784381609561\ \(0\)\
\-\ crying\\:\\ 0\\.006146055549531626\ \(0\)\
\-\ titers\\:\\ 0\\.006146055549531626\ \(0\)\
\-\ evolve\\:\\ 0\\.006146055549531626\ \(0\)\
\-\ extremities\\:\\ 0\\.006116216457921329\ \(0\)\
\-\ normal\\:\\ 0\\.006111370687039694\ \(0\)\
\-\ to\\:\\ 0\\.006039740584732014\ \(0\)\
\-\ preliminary\\:\\ 0\\.006038589276122517\ \(0\)\
\-\ frame\\:\\ 0\\.006038589276122517\ \(0\)\
\-\ preceding\\:\\ 0\\.006038589276122517\ \(0\)\
\-\ callosum\\:\\ 0\\.006000960253362022\ \(0\)\
\-\ 7\\.5\\:\\ 0\\.005942457418770485\ \(0\)\
\-\ no\\:\\ 0\\.005888075848794265\ \(0\)\
\-\ corpus\\:\\ 0\\.00576233791694125\ \(0\)\
\-\ rheumatology\\:\\ 0\\.005703073965789198\ \(0\)\
\-\ discharge\\:\\ 0\\.00566973940169424\ \(0\)\
\-\ strep\\:\\ 0\\.005635457202875218\ \(0\)\
\-\ spinal\\:\\ 0\\.005583533230619682\ \(0\)\
\-\ rigidity\\:\\ 0\\.005513621990626566\ \(0\)\
\-\ typically\\:\\ 0\\.00550442658668973\ \(0\)\
\-\ phase\\:\\ 0\\.005501452388279777\ \(0\)\
\-\ \\&\\:\\ 0\\.005476985204637649\ \(0\)\
\-\ ten\\:\\ 0\\.0054061557172174575\ \(0\)\
\-\ seen\\:\\ 0\\.005392515194103025\ \(0\)\
\-\ that\\:\\ 0\\.005386790980141691\ \(0\)\
\-\ also\\:\\ 0\\.005379715855698476\ \(0\)\
\-\ for\\:\\ 0\\.005321957289362884\ \(0\)\
\-\ perivascular\\:\\ 0\\.005310023859865426\ \(0\)\
\-\ can\\:\\ 0\\.005305353154568621\ \(0\)\
\-\ fever\\:\\ 0\\.005276026690788259\ \(0\)\
\-\ ambulation\\:\\ 0\\.005265507286718134\ \(0\)\
\-\ diffusion\\:\\ 0\\.005235062733377411\ \(0\)\
\-\ begin\\:\\ 0\\.005182503839450135\ \(0\)\
\-\ demyelination\\:\\ 0\\.005182503839450135\ \(0\)\
\-\ initial\\:\\ 0\\.005167120699414795\ \(0\)\
\-\ w\\:\\ 0\\.005143672074469482\ \(0\)\
\-\ represent\\:\\ 0\\.005136300261322352\ \(0\)\
\-\ study\\:\\ 0\\.00513071415485394\ \(0\)\
\-\ is\\:\\ 0\\.005130390313729248\ \(0\)\
\-\ have\\:\\ 0\\.005065067732751164\ \(0\)\
\-\ tumefactive\\:\\ 0\\.005036205801060374\ \(0\)\
\-\ on\\:\\ 0\\.004953633752500648\ \(0\)\
\-\ etiology\\:\\ 0\\.0049503030009589504\ \(0\)\
\-\ \\(\\:\\ 0\\.00494316874710671\ \(0\)\
\-\ ed\\:\\ 0\\.0049427624136264186\ \(0\)\
\-\ involved\\:\\ 0\\.0049056703564487845\ \(0\)\
\-\ \\)\\:\\ 0\\.004882785301870245\ \(0\)\
\-\ 99\\:\\ 0\\.0048811884317215065\ \(0\)\
\-\ demyelinating\\:\\ 0\\.004825873995757606\ \(0\)\
\-\ clinical\\:\\ 0\\.0047980105840620514\ \(0\)\
\-\ days\\:\\ 0\\.004779332657248134\ \(0\)\
\-\ increased\\:\\ 0\\.004768441564324032\ \(0\)\
\-\ neurology\\:\\ 0\\.004748723094272147\ \(0\)\
\-\ subcortical\\:\\ 0\\.004748723094272147\ \(0\)\
\-\ some\\:\\ 0\\.00473527053625321\ \(0\)\
\-\ deep\\:\\ 0\\.004733939985348293\ \(0\)\
\-\ considered\\:\\ 0\\.004721089063336651\ \(0\)\
\-\ cr\\:\\ 0\\.004677590300960367\ \(0\)\
\-\ \\‚\\Ä\\ô\\:\\ 0\\.004660632736579299\ \(0\)\
\-\ and\\:\\ 0\\.004598770219436238\ \(0\)\
\-\ mostly\\:\\ 0\\.004550070280545076\ \(0\)\
\-\ parents\\:\\ 0\\.004530447830525948\ \(0\)\
\-\ mri\\:\\ 0\\.004478275216502326\ \(0\)\
\-\ s\\:\\ 0\\.004472203772106911\ \(0\)\
\-\ two\\:\\ 0\\.004465932915357675\ \(0\)\
\-\ disease\\:\\ 0\\.004460384483809274\ \(0\)\
\-\ weeks\\:\\ 0\\.0044256893374108545\ \(0\)\
\-\ might\\:\\ 0\\.004420827108042314\ \(0\)\
\-\ commonly\\:\\ 0\\.0044131360996199475\ \(0\)\
\-\ all\\:\\ 0\\.004410444323779727\ \(0\)\
\-\ childhood\\:\\ 0\\.004387030327312068\ \(0\)\
\-\ brainstem\\:\\ 0\\.004370590085065099\ \(0\)\
\-\ studies\\:\\ 0\\.004367930088201405\ \(0\)\
\-\ affecting\\:\\ 0\\.004338572457500072\ \(0\)\
\-\ abnormalities\\:\\ 0\\.004295754500499384\ \(0\)\
\-\ are\\:\\ 0\\.004251364498283218\ \(0\)\
\-\ very\\:\\ 0\\.004245144550808115\ \(0\)\
\-\ been\\:\\ 0\\.004242326440627721\ \(0\)\
\-\ intensity\\:\\ 0\\.004227195268767292\ \(0\)\
\-\ touch\\:\\ 0\\.004206957850890084\ \(0\)\
\-\ glucose\\:\\ 0\\.004166991954303959\ \(0\)\
\-\ multiple\\:\\ 0\\.004105396905746507\ \(0\)\
\-\ reduced\\:\\ 0\\.004104042254042143\ \(0\)\
\-\ w\\/\\:\\ 0\\.004045156742055306\ \(0\)\
\-\ from\\:\\ 0\\.0040442746314231235\ \(0\)\
\-\ patients\\:\\ 0\\.004035720071835814\ \(0\)\
\-\ after\\:\\ 0\\.004032849458506392\ \(0\)\
\-\ 108\\-126\\/64\\-78\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 114\\-170\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 36\\.7\\-38\\.8\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 18\\.35kg\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ yelling\\/crying\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ glassy\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ well\\-visulaized\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ dry\\/cracked\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ wheeze\\/rhonchi\\/rales\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ nomral\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ ext\\/msk\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ edmea\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ hypersensative\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ stance\\/gait\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ sandpaper\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 11\\.2\\/34\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 654\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 30\\.13\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 1\\.016\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ col\\/ml\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 3\\.35\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ ibili\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 57\\.6\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ monocyte\\/macrophage\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ ferretin\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ borrelia\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ anti\\-dnase\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ panel2\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 4\\.1\\-6\\.0\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 4\\.8\\.\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 30\\.8\\.\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 699\\.\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ opthamology\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ catherizations\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ acyclrovir\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ jia\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ ddischarged\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ status\\/confusion\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ drifting\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ meylitis\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ expertise\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ c\\/t\\/l\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ cntr\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ subtle\\/mild\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ c4\\-t2\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ early\\/mild\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 4\\/28\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ 5\\/4\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ sel\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ panencephalitis\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ aidp\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ presentsto\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ myelopathies\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ anisotropy\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ paainfectious\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ antibody\\-antigen\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ astrocytosis\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ nonhemorrhagic\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ autoimmune\\/immunologic\\:\\ 0\\.004021678113123402\ \(0\)\
\-\ protein\\:\\ 0\\.004000640168908015\ \(0\)\
\-\ subacute\\:\\ 0\\.004000640168908015\ \(0\)\
\-\ analysis\\:\\ 0\\.003968622541342988\ \(0\)\
\-\ less\\:\\ 0\\.003960684312485423\ \(0\)\
\-\ t2\\-weighted\\:\\ 0\\.003947885085980254\ \(0\)\
\-\ rapid\\:\\ 0\\.003937690468646198\ \(0\)\
\-\ patient\\:\\ 0\\.003907809903815639\ \(0\)\
\-\ more\\:\\ 0\\.0038999567688178215\ \(0\)\
\-\ cases\\:\\ 0\\.0038961827517989952\ \(0\)\
\-\ five\\:\\ 0\\.0038883590623776986\ \(0\)\
\-\ 34\\:\\ 0\\.0038693498589991927\ \(0\)\
\-\ central\\:\\ 0\\.003848035616140455\ \(0\)\
\-\ erythema\\:\\ 0\\.003832479842267553\ \(0\)\
\-\ gray\\:\\ 0\\.003814588901219765\ \(0\)\
\-\ enhance\\:\\ 0\\.003771338683250254\ \(0\)\
\-\ images\\:\\ 0\\.003739196833826081\ \(0\)\
\-\ t1\\:\\ 0\\.0037068825769492387\ \(0\)\
\-\ 20\\-24\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ calm\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ distressed\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ tonsilar\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ strawberry\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ 2sec\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ cooperation\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ 32\\.4\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ anc\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ 23\\.6\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ tprotein\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ 305\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ 245\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ burgdorferi\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ aso\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ 2\\.5\\.\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ 0\\.55\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ out\\-patient\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ reconsidered\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ leukoencephalitis\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ catheterizations\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ everything\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ post\\-infectious\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ post\\-vaccination\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ tensor\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ immune\\-mediated\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ perivenular\\:\\ 0\\.0037054613336708724\ \(0\)\
\-\ area\\:\\ 0\\.003697768582300548\ \(0\)\
\-\ onset\\:\\ 0\\.003691726130372012\ \(0\)\
\-\ appropriate\\:\\ 0\\.003675206825898223\ \(0\)\
\-\ or\\:\\ 0\\.003655192514466086\ \(0\)\
\-\ received\\:\\ 0\\.0036234774977261927\ \(0\)\
\-\ unable\\:\\ 0\\.0036021751583128793\ \(0\)\
\-\ flair\\:\\ 0\\.003574524291985024\ \(0\)\
\-\ smiling\\:\\ 0\\.0035204863755923304\ \(0\)\
\-\ tms\\:\\ 0\\.0035204863755923304\ \(0\)\
\-\ derm\\:\\ 0\\.0035204863755923304\ \(0\)\
\-\ 199\\:\\ 0\\.0035204863755923304\ \(0\)\
\-\ 155\\:\\ 0\\.0035204863755923304\ \(0\)\
\-\ abs\\:\\ 0\\.0035204863755923304\ \(0\)\
\-\ triglyceride\\:\\ 0\\.0035204863755923304\ \(0\)\
\-\ banding\\:\\ 0\\.0035204863755923304\ \(0\)\
\-\ cow\\:\\ 0\\.0035204863755923304\ \(0\)\
\-\ blood\\-brain\\:\\ 0\\.0035204863755923304\ \(0\)\
\-\ guillain\\-barre\\:\\ 0\\.0035204863755923304\ \(0\)\
\-\ 10\\-30\\:\\ 0\\.0035204863755923304\ \(0\)\
\-\ disorder\\:\\ 0\\.0035025407678338717\ \(0\)\
\-\ there\\:\\ 0\\.003480973238499057\ \(0\)\
\-\ difficulty\\:\\ 0\\.003471608695137082\ \(0\)\
\-\ admission\\:\\ 0\\.0034358233729169354\ \(0\)\
\-\ exam\\:\\ 0\\.00342560937946996\ \(0\)\
\-\ the\\:\\ 0\\.003405776174268154\ \(0\)\
\-\ infection\\:\\ 0\\.003399657719990156\ \(0\)\
\-\ labia\\:\\ 0\\.0033892445542183427\ \(0\)\
\-\ enterococcus\\:\\ 0\\.0033892445542183427\ \(0\)\
\-\ 153\\:\\ 0\\.0033892445542183427\ \(0\)\
\-\ 0\\.0\\:\\ 0\\.0033892445542183427\ \(0\)\
\-\ weakly\\:\\ 0\\.0033892445542183427\ \(0\)\
\-\ heme\\/onc\\:\\ 0\\.0033892445542183427\ \(0\)\
\-\ nuc\\:\\ 0\\.0033892445542183427\ \(0\)\
\-\ averaging\\:\\ 0\\.0033892445542183427\ \(0\)\
\-\ mononuclear\\:\\ 0\\.0033892445542183427\ \(0\)\
\-\ oncologic\\:\\ 0\\.0033892445542183427\ \(0\)\
\-\ not\\:\\ 0\\.00337997811608194\ \(0\)\
\-\ affected\\:\\ 0\\.003373653842654875\ \(0\)\
\-\ had\\:\\ 0\\.0033646894511691755\ \(0\)\
\-\ resolution\\:\\ 0\\.0033627917053315917\ \(0\)\
\-\ foci\\:\\ 0\\.0033467371780593475\ \(0\)\
\-\ focal\\:\\ 0\\.0033400916115032876\ \(0\)\
\-\ time\\:\\ 0\\.0033032863511486942\ \(0\)\
\-\ likely\\:\\ 0\\.0032987545154228876\ \(0\)\
\-\ limited\\:\\ 0\\.003290175429858647\ \(0\)\
\-\ cool\\:\\ 0\\.0032874454888377727\ \(0\)\
\-\ cath\\:\\ 0\\.0032874454888377727\ \(0\)\
\-\ 135\\:\\ 0\\.0032874454888377727\ \(0\)\
\-\ dbili\\:\\ 0\\.0032874454888377727\ \(0\)\
\-\ synthesis\\:\\ 0\\.0032874454888377727\ \(0\)\
\-\ rocephin\\:\\ 0\\.0032874454888377727\ \(0\)\
\-\ rheumatologic\\:\\ 0\\.0032874454888377727\ \(0\)\
\-\ neuromyelitis\\:\\ 0\\.0032874454888377727\ \(0\)\
\-\ optica\\:\\ 0\\.0032874454888377727\ \(0\)\
\-\ devic\\:\\ 0\\.0032874454888377727\ \(0\)\
\-\ meningismus\\:\\ 0\\.0032874454888377727\ \(0\)\
\-\ illustrate\\:\\ 0\\.0032874454888377727\ \(0\)\
\-\ eye\\:\\ 0\\.003270446904299189\ \(0\)\
\-\ by\\:\\ 0\\.0032455996880585646\ \(0\)\
\-\ lips\\:\\ 0\\.0032042695961398003\ \(0\)\
\-\ segs\\:\\ 0\\.0032042695961398003\ \(0\)\
\-\ neutrophil\\:\\ 0\\.0032042695961398003\ \(0\)\
\-\ fibrinogen\\:\\ 0\\.0032042695961398003\ \(0\)\
\-\ rheumatologist\\:\\ 0\\.0032042695961398003\ \(0\)\
\-\ angio\\:\\ 0\\.0032042695961398003\ \(0\)\
\-\ pml\\:\\ 0\\.0032042695961398003\ \(0\)\
\-\ occurrences\\:\\ 0\\.0032042695961398003\ \(0\)\
\-\ hurt\\:\\ 0\\.0032042695961398003\ \(0\)\
\-\ high\\:\\ 0\\.00320056486461243\ \(0\)\
\-\ presenting\\:\\ 0\\.003177736889325848\ \(0\)\
\-\ conjunctivitis\\:\\ 0\\.003133945380890139\ \(0\)\
\-\ readmitted\\:\\ 0\\.003133945380890139\ \(0\)\
\-\ yesterday\\:\\ 0\\.003133945380890139\ \(0\)\
\-\ therapy\\:\\ 0\\.003126789410913248\ \(0\)\
\-\ signal\\:\\ 0\\.003083587130847781\ \(0\)\
\-\ empirically\\:\\ 0\\.003073027774765813\ \(0\)\
\-\ expressed\\:\\ 0\\.003073027774765813\ \(0\)\
\-\ refered\\:\\ 0\\.003073027774765813\ \(0\)\
\-\ complexes\\:\\ 0\\.003073027774765813\ \(0\)\
\-\ worsening\\:\\ 0\\.0030697809948912387\ \(0\)\
\-\ this\\:\\ 0\\.0030693250425177605\ \(0\)\
\-\ nc\\/at\\:\\ 0\\.0030192946380612584\ \(0\)\
\-\ s1\\/s2\\:\\ 0\\.0030192946380612584\ \(0\)\
\-\ responds\\:\\ 0\\.0030192946380612584\ \(0\)\
\-\ lymphocyte\\:\\ 0\\.0030192946380612584\ \(0\)\
\-\ titer\\:\\ 0\\.0030192946380612584\ \(0\)\
\-\ myelin\\:\\ 0\\.0030192946380612584\ \(0\)\
\-\ id\\:\\ 0\\.0030192946380612584\ \(0\)\
\-\ bilat\\:\\ 0\\.0030192946380612584\ \(0\)\
\-\ delineated\\:\\ 0\\.0030192946380612584\ \(0\)\
\-\ vaccination\\:\\ 0\\.0030192946380612584\ \(0\)\
\-\ nuchal\\:\\ 0\\.0030192946380612584\ \(0\)\
\-\ malignancy\\:\\ 0\\.003012855545439339\ \(0\)\
\-\ process\\:\\ 0\\.003001884566455031\ \(0\)\
\-\ over\\:\\ 0\\.0029776130339506787\ \(0\)\
\-\ exudate\\:\\ 0\\.0029712287093852426\ \(0\)\
\-\ nd\\:\\ 0\\.0029712287093852426\ \(0\)\
\-\ mono\\:\\ 0\\.0029712287093852426\ \(0\)\
\-\ 100\\,000\\:\\ 0\\.0029712287093852426\ \(0\)\
\-\ oligoclonal\\:\\ 0\\.0029712287093852426\ \(0\)\
\-\ immunoglobulin\\:\\ 0\\.0029712287093852426\ \(0\)\
\-\ necessitating\\:\\ 0\\.0029712287093852426\ \(0\)\
\-\ management\\:\\ 0\\.002942090733079965\ \(0\)\
\-\ course\\:\\ 0\\.002942090733079965\ \(0\)\
\-\ hospital\\:\\ 0\\.002935306993584054\ \(0\)\
\-\ rhinorrhea\\:\\ 0\\.002927747787941664\ \(0\)\
\-\ entry\\:\\ 0\\.002927747787941664\ \(0\)\
\-\ mycoplasma\\:\\ 0\\.002927747787941664\ \(0\)\
\-\ acyclovir\\:\\ 0\\.002927747787941664\ \(0\)\
\-\ ache\\:\\ 0\\.002927747787941664\ \(0\)\
\-\ supplemental\\:\\ 0\\.002927747787941664\ \(0\)\
\-\ bone\\:\\ 0\\.0029061606041877784\ \(0\)\
\-\ a\\:\\ 0\\.002894889064369352\ \(0\)\
\-\ hsm\\:\\ 0\\.0028880528166872707\ \(0\)\
\-\ tanner\\:\\ 0\\.0028880528166872707\ \(0\)\
\-\ diff\\:\\ 0\\.0028880528166872707\ \(0\)\
\-\ rpr\\:\\ 0\\.0028880528166872707\ \(0\)\
\-\ ck\\:\\ 0\\.0028880528166872707\ \(0\)\
\-\ uric\\:\\ 0\\.0028880528166872707\ \(0\)\
\-\ pcr\\:\\ 0\\.0028880528166872707\ \(0\)\
\-\ peduncle\\:\\ 0\\.0028880528166872707\ \(0\)\
\-\ distinction\\:\\ 0\\.0028880528166872707\ \(0\)\
\-\ involvement\\:\\ 0\\.002857608263346548\ \(0\)\
\-\ \\+bs\\:\\ 0\\.002851536982894599\ \(0\)\
\-\ vagina\\:\\ 0\\.002851536982894599\ \(0\)\
\-\ igm\\:\\ 0\\.002851536982894599\ \(0\)\
\-\ peduncles\\:\\ 0\\.002851536982894599\ \(0\)\
\-\ relaxation\\:\\ 0\\.002851536982894599\ \(0\)\
\-\ insult\\:\\ 0\\.002851536982894599\ \(0\)\
\-\ wbc\\:\\ 0\\.002842221578992529\ \(0\)\
\-\ cortical\\:\\ 0\\.002842221578992529\ \(0\)\
\-\ reported\\:\\ 0\\.002842221578992529\ \(0\)\
\-\ seem\\:\\ 0\\.002817728601437609\ \(0\)\
\-\ gravity\\:\\ 0\\.002817728601437609\ \(0\)\
\-\ ebv\\:\\ 0\\.002817728601437609\ \(0\)\
\-\ hsv\\:\\ 0\\.002817728601437609\ \(0\)\
\-\ breakdown\\:\\ 0\\.002817728601437609\ \(0\)\
\-\ thorough\\:\\ 0\\.002817728601437609\ \(0\)\
\-\ guide\\:\\ 0\\.002817728601437609\ \(0\)\
\-\ of\\:\\ 0\\.002816925840462312\ \(0\)\
\-\ otherwise\\:\\ 0\\.0028004701034911907\ \(0\)\
\-\ platelet\\:\\ 0\\.0027862537513067007\ \(0\)\
\-\ 3\\.9\\:\\ 0\\.0027862537513067007\ \(0\)\
\-\ clonus\\:\\ 0\\.0027862537513067007\ \(0\)\
\-\ barrier\\:\\ 0\\.0027862537513067007\ \(0\)\
\-\ clean\\:\\ 0\\.0027862537513067007\ \(0\)\
\-\ seemed\\:\\ 0\\.0027862537513067007\ \(0\)\
\-\ myelopathy\\:\\ 0\\.0027862537513067007\ \(0\)\
\-\ postcontrast\\:\\ 0\\.0027862537513067007\ \(0\)\
\-\ identified\\:\\ 0\\.002786010074075111\ \(0\)\
\-\ perrl\\:\\ 0\\.002756810995313283\ \(0\)\
\-\ 5\\.1\\:\\ 0\\.002756810995313283\ \(0\)\
\-\ aspirate\\:\\ 0\\.002756810995313283\ \(0\)\
\-\ ir\\:\\ 0\\.002756810995313283\ \(0\)\
\-\ multilevel\\:\\ 0\\.002756810995313283\ \(0\)\
\-\ hyperintensities\\:\\ 0\\.002756810995313283\ \(0\)\
\-\ h\\/h\\:\\ 0\\.002729153777331333\ \(0\)\
\-\ 92\\:\\ 0\\.002729153777331333\ \(0\)\
\-\ rf\\:\\ 0\\.002729153777331333\ \(0\)\
\-\ neuroimaging\\:\\ 0\\.002729153777331333\ \(0\)\
\-\ distinguishing\\:\\ 0\\.002729153777331333\ \(0\)\
\-\ \\%\\:\\ 0\\.0027280853558567623\ \(0\)\
\-\ inflammatory\\:\\ 0\\.0027037554235328685\ \(0\)\
\-\ localize\\:\\ 0\\.0027030778586087287\ \(0\)\
\-\ polyneuropathy\\:\\ 0\\.0027030778586087287\ \(0\)\
\-\ an\\:\\ 0\\.0026954034313064093\ \(0\)\
\-\ presentation\\:\\ 0\\.0026855845205210603\ \(0\)\
\-\ sclera\\:\\ 0\\.002678412155474479\ \(0\)\
\-\ vancomycin\\:\\ 0\\.002678412155474479\ \(0\)\
\-\ ecg\\:\\ 0\\.002678412155474479\ \(0\)\
\-\ ana\\:\\ 0\\.002655011929932713\ \(0\)\
\-\ presumptive\\:\\ 0\\.002655011929932713\ \(0\)\
\-\ week\\:\\ 0\\.0026478242867958284\ \(0\)\
\-\ present\\:\\ 0\\.0026414353384101473\ \(0\)\
\-\ masses\\:\\ 0\\.0026355770054708825\ \(0\)\
\-\ cl\\:\\ 0\\.002632753643359067\ \(0\)\
\-\ tbili\\:\\ 0\\.002632753643359067\ \(0\)\
\-\ possible\\:\\ 0\\.0026258961851132042\ \(0\)\
\-\ areas\\:\\ 0\\.002623491944567579\ \(0\)\
\-\ contrast\\:\\ 0\\.002617849936324688\ \(0\)\
\-\ check\\:\\ 0\\.002611531008489134\ \(0\)\
\-\ 0\\.4\\:\\ 0\\.002611531008489134\ \(0\)\
\-\ 3\\.4\\:\\ 0\\.002611531008489134\ \(0\)\
\-\ pulm\\:\\ 0\\.0025912519197250675\ \(0\)\
\-\ pale\\:\\ 0\\.0025912519197250675\ \(0\)\
\-\ pink\\:\\ 0\\.0025912519197250675\ \(0\)\
\-\ courses\\:\\ 0\\.0025912519197250675\ \(0\)\
\-\ nervous\\:\\ 0\\.0025912519197250675\ \(0\)\
\-\ \\'s\\:\\ 0\\.0025785309557943134\ \(0\)\
\-\ p\\.\\:\\ 0\\.002571836037234741\ \(0\)\
\-\ progressing\\:\\ 0\\.002571836037234741\ \(0\)\
\-\ bilaterally\\:\\ 0\\.002560862443908671\ \(0\)\
\-\ vascular\\:\\ 0\\.0025563898429960736\ \(0\)\
\-\ gu\\:\\ 0\\.002553212864552143\ \(0\)\
\-\ ph\\:\\ 0\\.002553212864552143\ \(0\)\
\-\ paresthesias\\:\\ 0\\.002553212864552143\ \(0\)\
\-\ occurrence\\:\\ 0\\.002553212864552143\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.0025365301016804214\ \(0\)\
\-\ profile\\:\\ 0\\.002535320203442069\ \(0\)\
\-\ acutely\\:\\ 0\\.002535320203442069\ \(0\)\
\-\ body\\:\\ 0\\.002532174920336756\ \(0\)\
\-\ positive\\:\\ 0\\.002530005100624194\ \(0\)\
\-\ impaired\\:\\ 0\\.002518102900530187\ \(0\)\
\-\ sharply\\:\\ 0\\.002518102900530187\ \(0\)\
\-\ several\\:\\ 0\\.0025064715654401345\ \(0\)\
\-\ wt\\:\\ 0\\.0025015118219850795\ \(0\)\
\-\ co2\\:\\ 0\\.0025015118219850795\ \(0\)\
\-\ cmv\\:\\ 0\\.0025015118219850795\ \(0\)\
\-\ school\\:\\ 0\\.0025015118219850795\ \(0\)\
\-\ permanent\\:\\ 0\\.0025015118219850795\ \(0\)\
\-\ but\\:\\ 0\\.0024943019630933455\ \(0\)\
\-\ basic\\:\\ 0\\.0024855030082025654\ \(0\)\
\-\ raised\\:\\ 0\\.0024855030082025654\ \(0\)\
\-\ further\\:\\ 0\\.0024794198374089946\ \(0\)\
\-\ day\\:\\ 0\\.0024753283114534027\ \(0\)\
\-\ differential\\:\\ 0\\.0024753283114534027\ \(0\)\
\-\ stopped\\:\\ 0\\.0024700369718541706\ \(0\)\
\-\ neuritis\\:\\ 0\\.0024700369718541706\ \(0\)\
\-\ pronounced\\:\\ 0\\.0024700369718541706\ \(0\)\
\-\ adjacent\\:\\ 0\\.002465179054867032\ \(0\)\
\-\ mellitus\\:\\ 0\\.0024550781110772592\ \(0\)\
\-\ mimic\\:\\ 0\\.0024550781110772592\ \(0\)\
\-\ consisting\\:\\ 0\\.0024550781110772592\ \(0\)\
\-\ coma\\:\\ 0\\.0024550781110772592\ \(0\)\
\-\ ldh\\:\\ 0\\.0024405942158607532\ \(0\)\
\-\ regimen\\:\\ 0\\.0024405942158607532\ \(0\)\
\-\ pineal\\:\\ 0\\.0024405942158607532\ \(0\)\
\-\ predominance\\:\\ 0\\.0024405942158607532\ \(0\)\
\-\ nuclei\\:\\ 0\\.0024405942158607532\ \(0\)\
\-\ hospitalization\\:\\ 0\\.002426556050410592\ \(0\)\
\-\ pounds\\:\\ 0\\.002426556050410592\ \(0\)\
\-\ infiltrates\\:\\ 0\\.002426556050410592\ \(0\)\
\-\ correlate\\:\\ 0\\.002426556050410592\ \(0\)\
\-\ supple\\:\\ 0\\.002412936997878803\ \(0\)\
\-\ ctab\\:\\ 0\\.002412936997878803\ \(0\)\
\-\ opening\\:\\ 0\\.002412936997878803\ \(0\)\
\-\ urology\\:\\ 0\\.002412936997878803\ \(0\)\
\-\ abrupt\\:\\ 0\\.002412936997878803\ \(0\)\
\-\ eomi\\:\\ 0\\.002399712756604509\ \(0\)\
\-\ amylase\\:\\ 0\\.002399712756604509\ \(0\)\
\-\ provider\\:\\ 0\\.002399712756604509\ \(0\)\
\-\ constipation\\:\\ 0\\.002399712756604509\ \(0\)\
\-\ lesser\\:\\ 0\\.002399712756604509\ \(0\)\
\-\ medical\\:\\ 0\\.0023990052920310257\ \(0\)\
\-\ crp\\:\\ 0\\.002386861079156199\ \(0\)\
\-\ lipase\\:\\ 0\\.002386861079156199\ \(0\)\
\-\ neg\\:\\ 0\\.002386861079156199\ \(0\)\
\-\ marginated\\:\\ 0\\.002386861079156199\ \(0\)\
\-\ tongue\\:\\ 0\\.0023743615471360736\ \(0\)\
\-\ rash\\:\\ 0\\.0023743615471360736\ \(0\)\
\-\ ingestion\\:\\ 0\\.0023743615471360736\ \(0\)\
\-\ usually\\:\\ 0\\.002367635268126605\ \(0\)\
\-\ suggestion\\:\\ 0\\.002362195376021949\ \(0\)\
\-\ column\\:\\ 0\\.0023503452453635275\ \(0\)\
\-\ specimen\\:\\ 0\\.0023387951504801833\ \(0\)\
\-\ confusion\\:\\ 0\\.0023387951504801833\ \(0\)\
\-\ negative\\:\\ 0\\.002328576789575615\ \(0\)\
\-\ sle\\:\\ 0\\.002327530272473627\ \(0\)\
\-\ techniques\\:\\ 0\\.002327530272473627\ \(0\)\
\-\ impairment\\:\\ 0\\.002327530272473627\ \(0\)\
\-\ consult\\:\\ 0\\.002316536863906537\ \(0\)\
\-\ preferred\\:\\ 0\\.002316536863906537\ \(0\)\
\-\ whereas\\:\\ 0\\.002316536863906537\ \(0\)\
\-\ g\\:\\ 0\\.002305802147934733\ \(0\)\
\-\ diagnoses\\:\\ 0\\.002305802147934733\ \(0\)\
\-\ sclerosing\\:\\ 0\\.002305802147934733\ \(0\)\
\-\ resolve\\:\\ 0\\.002305802147934733\ \(0\)\
\-\ panel\\:\\ 0\\.0022953142290366045\ \(0\)\
\-\ whole\\:\\ 0\\.0022953142290366045\ \(0\)\
\-\ others\\:\\ 0\\.0022953142290366045\ \(0\)\
\-\ acid\\:\\ 0\\.002285062013775629\ \(0\)\
\-\ potentially\\:\\ 0\\.002285062013775629\ \(0\)\
\-\ fairly\\:\\ 0\\.002285062013775629\ \(0\)\
\-\ 5\\:\\ 0\\.002281168268653434\ \(0\)\
\-\ alk\\:\\ 0\\.002275035140272538\ \(0\)\
\-\ phos\\:\\ 0\\.002275035140272538\ \(0\)\
\-\ average\\:\\ 0\\.002275035140272538\ \(0\)\
\-\ index\\:\\ 0\\.002265223915262974\ \(0\)\
\-\ strong\\:\\ 0\\.002265223915262974\ \(0\)\
\-\ repeated\\:\\ 0\\.0022556192577822113\ \(0\)\
\-\ receiving\\:\\ 0\\.0022556192577822113\ \(0\)\
\-\ fine\\:\\ 0\\.0022462126486568756\ \(0\)\
\-\ band\\:\\ 0\\.0022462126486568756\ \(0\)\
\-\ rbc\\:\\ 0\\.0022462126486568756\ \(0\)\
\-\ completed\\:\\ 0\\.0022462126486568756\ \(0\)\
\-\ periventricular\\:\\ 0\\.0022462126486568756\ \(0\)\
\-\ oxygen\\:\\ 0\\.002236996085099613\ \(0\)\
\-\ changes\\:\\ 0\\.0022345328250319894\ \(0\)\
\-\ appearance\\:\\ 0\\.002229841767093651\ \(0\)\
\-\ throat\\:\\ 0\\.0022279620398002607\ \(0\)\
\-\ sulci\\:\\ 0\\.0022279620398002607\ \(0\)\
\-\ surrounded\\:\\ 0\\.0022279620398002607\ \(0\)\
\-\ moderately\\:\\ 0\\.0022279620398002607\ \(0\)\
\-\ extremely\\:\\ 0\\.0022191034239895393\ \(0\)\
\-\ collagen\\:\\ 0\\.0022191034239895393\ \(0\)\
\-\ presumed\\:\\ 0\\.002210413554021157\ \(0\)\
\-\ ages\\:\\ 0\\.002210413554021157\ \(0\)\
\-\ water\\:\\ 0\\.002210413554021157\ \(0\)\
\-\ questionable\\:\\ 0\\.0022018861210776567\ \(0\)\
\-\ floor\\:\\ 0\\.002193515163656034\ \(0\)\
\-\ edge\\:\\ 0\\.0021852950425325494\ \(0\)\
\-\ tone\\:\\ 0\\.0021852950425325494\ \(0\)\
\-\ mra\\:\\ 0\\.0021852950425325494\ \(0\)\
\-\ which\\:\\ 0\\.0021831358402042184\ \(0\)\
\-\ scan\\:\\ 0\\.002182729434701623\ \(0\)\
\-\ consideration\\:\\ 0\\.002177220417943407\ \(0\)\
\-\ however\\:\\ 0\\.002170956255106816\ \(0\)\
\-\ 5\\/5\\:\\ 0\\.002169286228750036\ \(0\)\
\-\ evaluating\\:\\ 0\\.002169286228750036\ \(0\)\
\-\ cv\\:\\ 0\\.0021614876733853914\ \(0\)\
\-\ hiv\\:\\ 0\\.0021614876733853914\ \(0\)\
\-\ rapidly\\:\\ 0\\.0021614876733853914\ \(0\)\
\-\ bun\\:\\ 0\\.0021538201924016414\ \(0\)\
\-\ history\\:\\ 0\\.002153676163699057\ \(0\)\
\-\ gen\\:\\ 0\\.0021462794524603956\ \(0\)\
\-\ t1\\-weighted\\:\\ 0\\.002138861331624729\ \(0\)\
\-\ blood\\:\\ 0\\.002128112292435492\ \(0\)\
\-\ k\\:\\ 0\\.0021243774364082236\ \(0\)\
\-\ recovery\\:\\ 0\\.0021243774364082236\ \(0\)\
\-\ ast\\:\\ 0\\.0021173043586089693\ \(0\)\
\-\ alt\\:\\ 0\\.0021173043586089693\ \(0\)\
\-\ remarkable\\:\\ 0\\.0021173043586089693\ \(0\)\
\-\ sensitive\\:\\ 0\\.0021173043586089693\ \(0\)\
\-\ if\\:\\ 0\\.0021156418191429155\ \(0\)\
\-\ one\\:\\ 0\\.0021128935979111718\ \(0\)\
\-\ disk\\:\\ 0\\.002110339270958062\ \(0\)\
\-\ \\.\\:\\ 0\\.0021053556992039306\ \(0\)\
\-\ na\\:\\ 0\\.002103478925445042\ \(0\)\
\-\ 43\\:\\ 0\\.002103478925445042\ \(0\)\
\-\ services\\:\\ 0\\.002103478925445042\ \(0\)\
\-\ final\\:\\ 0\\.002103478925445042\ \(0\)\
\-\ death\\:\\ 0\\.002103478925445042\ \(0\)\
\-\ 66\\:\\ 0\\.0020967202184262734\ \(0\)\
\-\ reference\\:\\ 0\\.0020967202184262734\ \(0\)\
\-\ infarcts\\:\\ 0\\.0020967202184262734\ \(0\)\
\-\ patchy\\:\\ 0\\.0020900601821939955\ \(0\)\
\-\ straight\\:\\ 0\\.0020834959771519794\ \(0\)\
\-\ differentiated\\:\\ 0\\.0020834959771519794\ \(0\)\
\-\ make\\:\\ 0\\.0020834959771519794\ \(0\)\
\-\ hemispheres\\:\\ 0\\.00207702488454616\ \(0\)\
\-\ differentiation\\:\\ 0\\.00207702488454616\ \(0\)\
\-\ improve\\:\\ 0\\.00207702488454616\ \(0\)\
\-\ ua\\:\\ 0\\.0020706442997036694\ \(0\)\
\-\ prolonged\\:\\ 0\\.0020706442997036694\ \(0\)\
\-\ abd\\:\\ 0\\.0020643517257381877\ \(0\)\
\-\ half\\:\\ 0\\.002058144767683544\ \(0\)\
\-\ concerning\\:\\ 0\\.0020459785965694192\ \(0\)\
\-\ than\\:\\ 0\\.0020429277873341913\ \(0\)\
\-\ dose\\:\\ 0\\.0020400150557084006\ \(0\)\
\-\ developing\\:\\ 0\\.0020400150557084006\ \(0\)\
\-\ group\\:\\ 0\\.00202831686655998\ \(0\)\
\-\ echo\\:\\ 0\\.00202831686655998\ \(0\)\
\-\ murmur\\:\\ 0\\.0020169111629991143\ \(0\)\
\-\ pulses\\:\\ 0\\.0020169111629991143\ \(0\)\
\-\ choice\\:\\ 0\\.0020169111629991143\ \(0\)\
\-\ helpful\\:\\ 0\\.0020169111629991143\ \(0\)\
\-\ neuro\\:\\ 0\\.0020113134930210973\ \(0\)\
\-\ cultures\\:\\ 0\\.002005783675259991\ \(0\)\
\-\ nonspecific\\:\\ 0\\.002005783675259991\ \(0\)\
\-\ leukemia\\:\\ 0\\.0020003200844540075\ \(0\)\
\-\ drug\\:\\ 0\\.0020003200844540075\ \(0\)\
\-\ 2\\+\\:\\ 0\\.001994921153045703\ \(0\)\
\-\ once\\:\\ 0\\.001994921153045703\ \(0\)\
\-\ antibiotic\\:\\ 0\\.001994921153045703\ \(0\)\
\-\ returned\\:\\ 0\\.001994921153045703\ \(0\)\
\-\ bacterial\\:\\ 0\\.001994921153045703\ \(0\)\
\-\ rr\\:\\ 0\\.0019895853684822034\ \(0\)\
\-\ rrr\\:\\ 0\\.0019895853684822034\ \(0\)\
\-\ adults\\:\\ 0\\.0019895853684822034\ \(0\)\
\-\ sometimes\\:\\ 0\\.001984311270671494\ \(0\)\
\-\ consciousness\\:\\ 0\\.0019790974495840744\ \(0\)\
\-\ esr\\:\\ 0\\.001973942542990127\ \(0\)\
\-\ viral\\:\\ 0\\.001963804250661336\ \(0\)\
\-\ adult\\:\\ 0\\.001953886373546187\ \(0\)\
\-\ response\\:\\ 0\\.001953886373546187\ \(0\)\
\-\ movement\\:\\ 0\\.0019490071358104445\ \(0\)\
\-\ d\\:\\ 0\\.0019441795311888493\ \(0\)\
\-\ serial\\:\\ 0\\.0019441795311888493\ \(0\)\
\-\ occlusion\\:\\ 0\\.0019441795311888493\ \(0\)\
\-\ number\\:\\ 0\\.0019441795311888493\ \(0\)\
\-\ characterized\\:\\ 0\\.0019394024783296816\ \(0\)\
\-\ conditions\\:\\ 0\\.0019394024783296816\ \(0\)\
\-\ cerebellum\\:\\ 0\\.0019394024783296816\ \(0\)\
\-\ extent\\:\\ 0\\.0019346749294995964\ \(0\)\
\-\ episodes\\:\\ 0\\.0019253643128795202\ \(0\)\
\-\ normally\\:\\ 0\\.0019207793056470832\ \(0\)\
\-\ epidural\\:\\ 0\\.0019207793056470832\ \(0\)\
\-\ higher\\:\\ 0\\.001911745260347731\ \(0\)\
\-\ 48\\:\\ 0\\.0019072944506098824\ \(0\)\
\-\ poorly\\:\\ 0\\.0019028866445370098\ \(0\)\
\-\ hr\\:\\ 0\\.0018985210190734375\ \(0\)\
\-\ asymmetric\\:\\ 0\\.0018941967745686275\ \(0\)\
\-\ bilateral\\:\\ 0\\.0018921694610533248\ \(0\)\
\-\ times\\:\\ 0\\.0018899131338980801\ \(0\)\
\-\ heent\\:\\ 0\\.001885669341625127\ \(0\)\
\-\ angiogram\\:\\ 0\\.001885669341625127\ \(0\)\
\-\ pediatric\\:\\ 0\\.0018772983842035044\ \(0\)\
\-\ again\\:\\ 0\\.001873169809605002\ \(0\)\
\-\ systemic\\:\\ 0\\.0018650230863385753\ \(0\)\
\-\ disorders\\:\\ 0\\.0018650230863385753\ \(0\)\
\-\ 1\\:\\ 0\\.001855224788284404\ \(0\)\
\-\ 23\\:\\ 0\\.0018530694492975063\ \(0\)\
\-\ fevers\\:\\ 0\\.0018530694492975063\ \(0\)\
\-\ our\\:\\ 0\\.0018530694492975063\ \(0\)\
\-\ noted\\:\\ 0\\.0018480120332596656\ \(0\)\
\-\ volume\\:\\ 0\\.0018414210450980696\ \(0\)\
\-\ able\\:\\ 0\\.0018376034129491115\ \(0\)\
\-\ b\\:\\ 0\\.0018376034129491115\ \(0\)\
\-\ reduction\\:\\ 0\\.0018376034129491115\ \(0\)\
\-\ involve\\:\\ 0\\.0018376034129491115\ \(0\)\
\-\ 90\\:\\ 0\\.0018376034129491115\ \(0\)\
\-\ felt\\:\\ 0\\.0018338174627599256\ \(0\)\
\-\ improvement\\:\\ 0\\.0018189802402665133\ \(0\)\
\-\ mental\\:\\ 0\\.0018189802402665133\ \(0\)\
\-\ hemorrhagic\\:\\ 0\\.0018189802402665133\ \(0\)\
\-\ scans\\:\\ 0\\.0018153451263754653\ \(0\)\
\-\ with\\:\\ 0\\.0018148457970147132\ \(0\)\
\-\ t\\:\\ 0\\.0018046104104036615\ \(0\)\
\-\ optic\\:\\ 0\\.0018046104104036615\ \(0\)\
\-\ problems\\:\\ 0\\.0018046104104036615\ \(0\)\
\-\ complaint\\:\\ 0\\.0018010875791564396\ \(0\)\
\-\ most\\:\\ 0\\.0018000320636205073\ \(0\)\
\-\ rest\\:\\ 0\\.0017975917430498843\ \(0\)\
\-\ included\\:\\ 0\\.0017975917430498843\ \(0\)\
\-\ subtle\\:\\ 0\\.0017906794232412156\ \(0\)\
\-\ discharged\\:\\ 0\\.001787262145992512\ \(0\)\
\-\ incidence\\:\\ 0\\.001787262145992512\ \(0\)\
\-\ evident\\:\\ 0\\.0017838702762445569\ \(0\)\
\-\ deficits\\:\\ 0\\.0017838702762445569\ \(0\)\
\-\ mother\\:\\ 0\\.0017805034389737438\ \(0\)\
\-\ lack\\:\\ 0\\.001773843402741466\ \(0\)\
\-\ were\\:\\ 0\\.0017703342488046725\ \(0\)\
\-\ healthy\\:\\ 0\\.0017576066577128608\ \(0\)\
\-\ poor\\:\\ 0\\.0017544275202511393\ \(0\)\
\-\ generally\\:\\ 0\\.0017544275202511393\ \(0\)\
\-\ carotid\\:\\ 0\\.0017481349462856578\ \(0\)\
\-\ ventricular\\:\\ 0\\.0017419279882310143\ \(0\)\
\-\ started\\:\\ 0\\.0017388558932577732\ \(0\)\
\-\ herniation\\:\\ 0\\.001735804347568541\ \(0\)\
\-\ strength\\:\\ 0\\.0017297618171168896\ \(0\)\
\-\ surface\\:\\ 0\\.0017208454867916293\ \(0\)\
\-\ 14\\:\\ 0\\.0017179116864584677\ \(0\)\
\-\ marrow\\:\\ 0\\.001714996632581291\ \(0\)\
\-\ clinically\\:\\ 0\\.001709221816490085\ \(0\)\
\-\ difficult\\:\\ 0\\.0017063615915751237\ \(0\)\
\-\ recurrence\\:\\ 0\\.0017006943835465849\ \(0\)\
\-\ segment\\:\\ 0\\.0017006943835465849\ \(0\)\
\-\ young\\:\\ 0\\.0016978869631203175\ \(0\)\
\-\ growth\\:\\ 0\\.0016950967135685672\ \(0\)\
\-\ bp\\:\\ 0\\.0016923234261249623\ \(0\)\
\-\ review\\:\\ 0\\.0016895668958074612\ \(0\)\
\-\ frequently\\:\\ 0\\.0016895668958074612\ \(0\)\
\-\ pending\\:\\ 0\\.0016868269213274375\ \(0\)\
\-\ neurological\\:\\ 0\\.0016868269213274375\ \(0\)\
\-\ admitted\\:\\ 0\\.0016841033050014776\ \(0\)\
\-\ children\\:\\ 0\\.0016841033050014776\ \(0\)\
\-\ full\\:\\ 0\\.0016841033050014776\ \(0\)\
\-\ cerebellar\\:\\ 0\\.0016813958526657959\ \(0\)\
\-\ 2\\:\\ 0\\.0016789274603198415\ \(0\)\
\-\ total\\:\\ 0\\.0016787043735931734\ \(0\)\
\-\ continued\\:\\ 0\\.0016787043735931734\ \(0\)\
\-\ another\\:\\ 0\\.0016760286804123347\ \(0\)\
\-\ seizures\\:\\ 0\\.0016760286804123347\ \(0\)\
\-\ intermittent\\:\\ 0\\.0016733685890296737\ \(0\)\
\-\ good\\:\\ 0\\.001668094491218964\ \(0\)\
\-\ suggestive\\:\\ 0\\.0016654801323188796\ \(0\)\
\-\ described\\:\\ 0\\.0016602959358543198\ \(0\)\
\-\ findings\\:\\ 0\\.0016595227516331748\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.0016577257635375972\ \(0\)\
\-\ inflammation\\:\\ 0\\.0016577257635375972\ \(0\)\
\-\ function\\:\\ 0\\.0016526284548705693\ \(0\)\
\-\ before\\:\\ 0\\.0016501010003196499\ \(0\)\
\-\ and\\/or\\:\\ 0\\.001647587471208806\ \(0\)\
\-\ general\\:\\ 0\\.0016426015813674783\ \(0\)\
\-\ oral\\:\\ 0\\.0016426015813674783\ \(0\)\
\-\ previously\\:\\ 0\\.0016376695940936573\ \(0\)\
\-\ caused\\:\\ 0\\.0016352234521495946\ \(0\)\
\-\ traumatic\\:\\ 0\\.0016327903563579146\ \(0\)\
\-\ hepatic\\:\\ 0\\.0016279627517363194\ \(0\)\
\-\ just\\:\\ 0\\.0016279627517363194\ \(0\)\
\-\ sequences\\:\\ 0\\.0016279627517363194\ \(0\)\
\-\ hyperintense\\:\\ 0\\.0016184581500470667\ \(0\)\
\-\ administration\\:\\ 0\\.0016184581500470667\ \(0\)\
\-\ recommended\\:\\ 0\\.0016161126210778975\ \(0\)\
\-\ specific\\:\\ 0\\.001611457433954612\ \(0\)\
\-\ female\\:\\ 0\\.001602883459350213\ \(0\)\
\-\ thin\\:\\ 0\\.0016022871879139702\ \(0\)\
\-\ many\\:\\ 0\\.0016022871879139702\ \(0\)\
\-\ occurs\\:\\ 0\\.001600023141681247\ \(0\)\
\-\ family\\:\\ 0\\.0015977702759693022\ \(0\)\
\-\ appear\\:\\ 0\\.0015955284808952014\ \(0\)\
\-\ upon\\:\\ 0\\.0015932976481879972\ \(0\)\
\-\ where\\:\\ 0\\.0015910776711573526\ \(0\)\
\-\ lesion\\:\\ 0\\.0015880978339420206\ \(0\)\
\-\ bladder\\:\\ 0\\.0015823042396209076\ \(0\)\
\-\ lymph\\:\\ 0\\.0015736963544455505\ \(0\)\
\-\ results\\:\\ 0\\.0015736963544455505\ \(0\)\
\-\ range\\:\\ 0\\.0015694525621725971\ \(0\)\
\-\ motion\\:\\ 0\\.0015673453788439956\ \(0\)\
\-\ typical\\:\\ 0\\.0015631599882071155\ \(0\)\
\-\ extensive\\:\\ 0\\.0015590126471025298\ \(0\)\
\-\ made\\:\\ 0\\.00155286148362749\ \(0\)\
\-\ enlargement\\:\\ 0\\.0015467921562432004\ \(0\)\
\-\ progressive\\:\\ 0\\.0015408025159869081\ \(0\)\
\-\ vs\\:\\ 0\\.0015348904974456193\ \(0\)\
\-\ minimal\\:\\ 0\\.0015348904974456193\ \(0\)\
\-\ system\\:\\ 0\\.0015348904974456193\ \(0\)\
\-\ moderate\\:\\ 0\\.0015329367283799253\ \(0\)\
\-\ similar\\:\\ 0\\.0015290541144803323\ \(0\)\
\-\ unknown\\:\\ 0\\.0015213866334965814\ \(0\)\
\-\ rate\\:\\ 0\\.0015194897310564976\ \(0\)\
\-\ change\\:\\ 0\\.0015194897310564976\ \(0\)\
\-\ \\<\\:\\ 0\\.001504591937728919\ \(0\)\
\-\ about\\:\\ 0\\.0015027634608139834\ \(0\)\
\-\ thoracic\\:\\ 0\\.0015027634608139834\ \(0\)\
\-\ second\\:\\ 0\\.0014973215945433293\ \(0\)\
\-\ used\\:\\ 0\\.0014955219694105665\ \(0\)\
\-\ active\\:\\ 0\\.0014883936309511316\ \(0\)\
\-\ vomiting\\:\\ 0\\.0014883936309511316\ \(0\)\
\-\ 50\\:\\ 0\\.0014831195331404218\ \(0\)\
\-\ referred\\:\\ 0\\.0014710453665399824\ \(0\)\
\-\ antibiotics\\:\\ 0\\.0014642866595212139\ \(0\)\
\-\ tumors\\:\\ 0\\.0014642866595212139\ \(0\)\
\-\ has\\:\\ 0\\.001464142308845144\ \(0\)\
\-\ occur\\:\\ 0\\.0014626125131302638\ \(0\)\
\-\ throughout\\:\\ 0\\.0014592825393704044\ \(0\)\
\-\ compression\\:\\ 0\\.0014592825393704044\ \(0\)\
\-\ 8\\:\\ 0\\.0014576266232889361\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.0014559766960671348\ \(0\)\
\-\ weakness\\:\\ 0\\.0014478153982793725\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.0014478153982793725\ \(0\)\
\-\ clear\\:\\ 0\\.001441389878260331\ \(0\)\
\-\ could\\:\\ 0\\.0014382107407986096\ \(0\)\
\-\ pain\\:\\ 0\\.001428295849722721\ \(0\)\
\-\ middle\\:\\ 0\\.0014257112087784844\ \(0\)\
\-\ iv\\:\\ 0\\.0014226391138052435\ \(0\)\
\-\ presence\\:\\ 0\\.0014150481836027048\ \(0\)\
\-\ venous\\:\\ 0\\.0014150481836027048\ \(0\)\
\-\ peripheral\\:\\ 0\\.0014105535228166593\ \(0\)\
\-\ care\\:\\ 0\\.0014061027130788104\ \(0\)\
\-\ required\\:\\ 0\\.0014031594488080584\ \(0\)\
\-\ 20\\:\\ 0\\.0014016949070059378\ \(0\)\
\-\ weight\\:\\ 0\\.0013973292815423655\ \(0\)\
\-\ would\\:\\ 0\\.0013873024080392744\ \(0\)\
\-\ hematoma\\:\\ 0\\.0013873024080392744\ \(0\)\
\-\ obtained\\:\\ 0\\.0013858878196824095\ \(0\)\
\-\ palpable\\:\\ 0\\.0013816701836677876\ \(0\)\
\-\ effect\\:\\ 0\\.001380272925670276\ \(0\)\
\-\ complete\\:\\ 0\\.00137197807207393\ \(0\)\
\-\ girl\\:\\ 0\\.0013706101418749078\ \(0\)\
\-\ new\\:\\ 0\\.0013584799164236125\ \(0\)\
\-\ labs\\:\\ 0\\.001355827557908366\ \(0\)\
\-\ side\\:\\ 0\\.0013505686595639008\ \(0\)\
\-\ headache\\:\\ 0\\.0013389532105683385\ \(0\)\
\-\ given\\:\\ 0\\.0013364116754180394\ \(0\)\
\-\ 3\\.\\:\\ 0\\.00133388422086712\ \(0\)\
\-\ now\\:\\ 0\\.0013326257252288538\ \(0\)\
\-\ neoplasm\\:\\ 0\\.001327626175142303\ \(0\)\
\-\ air\\:\\ 0\\.0013190066726970647\ \(0\)\
\-\ cause\\:\\ 0\\.0013190066726970647\ \(0\)\
\-\ type\\:\\ 0\\.0013141533888443933\ \(0\)\
\-\ first\\:\\ 0\\.001308158501270918\ \(0\)\
\-\ palpation\\:\\ 0\\.0013010670986989287\ \(0\)\
\-\ swelling\\:\\ 0\\.0012987275839329983\ \(0\)\
\-\ \\>\\:\\ 0\\.0012952406545020823\ \(0\)\
\-\ out\\:\\ 0\\.0012883457467420237\ \(0\)\
\-\ back\\:\\ 0\\.0012860704084614403\ \(0\)\
\-\ finding\\:\\ 0\\.0012564149201817888\ \(0\)\
\-\ should\\:\\ 0\\.00124279586765\ \(0\)\
\-\ 2\\.\\:\\ 0\\.0012397099187044973\ \(0\)\
\-\ past\\:\\ 0\\.0012386858904865118\ \(0\)\
\-\ between\\:\\ 0\\.0012356275256497462\ \(0\)\
\-\ abscess\\:\\ 0\\.001232589527433516\ \(0\)\
\-\ found\\:\\ 0\\.0012285700795858175\ \(0\)\
\-\ any\\:\\ 0\\.0012275707267665572\ \(0\)\
\-\ while\\:\\ 0\\.0012265735583267853\ \(0\)\
\-\ bowel\\:\\ 0\\.001222606538724799\ \(0\)\
\-\ such\\:\\ 0\\.0012186737179930894\ \(0\)\
\-\ 1\\.\\:\\ 0\\.0012176957875445259\ \(0\)\
\-\ examination\\:\\ 0\\.001211871822752995\ \(0\)\
\-\ approximately\\:\\ 0\\.001206121271238861\ \(0\)\
\-\ age\\:\\ 0\\.0011865466813614537\ \(0\)\
\-\ diffuse\\:\\ 0\\.0011802041151347238\ \(0\)\
\-\ treated\\:\\ 0\\.0011669027536878919\ \(0\)\
\-\ 6\\:\\ 0\\.0011642883947878076\ \(0\)\
\-\ primary\\:\\ 0\\.0011548285870874528\ \(0\)\
\-\ neck\\:\\ 0\\.0011447277084938332\ \(0\)\
\-\ demonstrated\\:\\ 0\\.0011438959773982516\ \(0\)\
\-\ loss\\:\\ 0\\.0011315986188268428\ \(0\)\
\-\ syndrome\\:\\ 0\\.0011149208835468255\ \(0\)\
\-\ axial\\:\\ 0\\.0011125873522207443\ \(0\)\
\-\ fluid\\:\\ 0\\.0011079557958959183\ \(0\)\
\-\ head\\:\\ 0\\.0011056575321961204\ \(0\)\
\-\ edema\\:\\ 0\\.0011026110809449318\ \(0\)\
\-\ include\\:\\ 0\\.001093591919721846\ \(0\)\
\-\ secondary\\:\\ 0\\.0010898859336262807\ \(0\)\
\-\ 4\\:\\ 0\\.0010862098107568636\ \(0\)\
\-\ y\\/o\\:\\ 0\\.0010796665282023909\ \(0\)\
\-\ shows\\:\\ 0\\.0010717945710441966\ \(0\)\
\-\ at\\:\\ 0\\.0010563532416347015\ \(0\)\
\-\ significant\\:\\ 0\\.0010482879338751018\ \(0\)\
\-\ cyst\\:\\ 0\\.0010476145693549739\ \(0\)\
\-\ enhancement\\:\\ 0\\.001044931006442991\ \(0\)\
\-\ mild\\:\\ 0\\.0010265754808080005\ \(0\)\
\-\ evidence\\:\\ 0\\.001022099718689269\ \(0\)\
\-\ common\\:\\ 0\\.0010201948959655096\ \(0\)\
\-\ these\\:\\ 0\\.0010145276879369707\ \(0\)\
\-\ abdominal\\:\\ 0\\.0009744157108221329\ \(0\)\
\-\ consistent\\:\\ 0\\.0009558842467295635\ \(0\)\
\-\ soft\\:\\ 0\\.000949327903281729\ \(0\)\
\-\ upper\\:\\ 0\\.0009407301575587218\ \(0\)\
\-\ without\\:\\ 0\\.0009178892182290877\ \(0\)\
\-\ other\\:\\ 0\\.0008985577320722849\ \(0\)\
\-\ small\\:\\ 0\\.0008980726662322622\ \(0\)\
\-\ demonstrate\\:\\ 0\\.0008971040790752922\ \(0\)\
\-\ lower\\:\\ 0\\.0008767618929579665\ \(0\)\
\-\ it\\:\\ 0\\.0008762994454986389\ \(0\)\
\-\ large\\:\\ 0\\.0008524372407988502\ \(0\)\
\-\ demonstrates\\:\\ 0\\.0008515607671775484\ \(0\)\
\-\ right\\:\\ 0\\.0008226566688963655\ \(0\)\
\-\ treatment\\:\\ 0\\.0007890588319347112\ \(0\)\
\-\ ct\\:\\ 0\\.0005453027615839612\ \(0\)\
\-\ mass\\:\\ 0\\.0005421811163081955\ \(0\)\
\-\ left\\:\\ 0\\.00043617941116465086\ \(0\)\
